

<insert date>

Dear Colleague,

**NICE Medical Technologies Evaluation Programme – invitation to comment – <insert technology>**

I am writing to you as your organisation may be interested in being involved in the development of [NICE Medical Technologies guidance](#) on the use of <insert technology> for <insert technology>. This technology has been notified to the [Medical Technologies Advisory Committee](#), which will develop guidance for the NHS on the adoption and use of this technology.

**How can you be involved?**

As part of NICE's commitment to involving patients and the public in the production of medical technologies guidance, we would like to invite your organisation to submit a written statement to NICE about the technology. Your organisation's statement will then be presented to the committee along with the research evidence and advice from clinical experts.

Areas that you may be able to provide information to NICE about might include:

1. **Information about any aspects of current management of <insert condition> which might be improved by patients or carers having access to or using <insert technology>**
2. **Information about possible disadvantages of the <insert technology> for patients and/or carers.**
3. **Identifiable sub groups of patients (for example, those protected by equalities legislation):**
  - a. for whom the <insert technology> would provide increased benefit,
  - b. for whom the <insert technology> would address an unmet need, or
  - c. who would be disadvantaged by the <insert technology> being unavailable.

4. **Identifiable sub groups of patients (for example, those protected by equalities legislation) for whom <insert technology> would not be appropriate**
5. **Potential impact for patients and carers if <insert technology> is not adopted by the NHS**
6. **Any other information specific to <insert technology> about which patients and/or carers might have particular insights.**

Please submit your statement to [laura.norburn@nice.org.uk](mailto:laura.norburn@nice.org.uk) by <insert date>.

Please note that your statement should not exceed 4 pages of A4 and that statements submitted after the deadline may not be considered.

We will accept joint statements from two or more organisations. These must be accompanied by a letter from each participating organisation to confirm their support of the statement.

## **Consultation**

NICE also encourages patient organisations and individual patients or carers, to comment on its draft recommendations.

A public consultation will take place for 4 weeks after the draft recommendations have been made by MTAC. There are a number of ways you can take part in this consultation:

- by commenting on the draft recommendations as an organisation with expert knowledge on patient needs and preferences in this area
- by publicising the consultation to your members
  - on your website
  - in a newsletter
  - through local support groups

At the moment this technology is scheduled to be considered by the Medical Technologies Advisory Committee in <insert month> with provisional recommendations being published in <insert month>. Please note that this timetable is subject to change.

## **NICE meetings are now in public**

You may also be interested to know that all NICE committee meetings are held in public. Information about attending committee meetings at NICE can be found on the NICE website here:

<http://www.nice.org.uk/newsroom/publicmeetings/advisorycommitteemeetings/advisorycommittees.jsp>

If you would like to attend the meeting where the above technology will be discussed you will need to register on the NICE website. Registration opens

20 working days before the meeting date and a provisional agenda will be posted at the same time.

If you have any queries regarding patient involvement in the Medical Technologies Evaluation Programme please do not hesitate to contact me.

Kind regards,

Laura